Global Anti-amyloid-β Monoclonal Antibodies Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Page: 83

Published Date: 27 Oct 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Anti-amyloid-β monoclonal antibodies are a class of targeted biologic therapies designed to bind specifically to amyloid-beta peptides in the brain, which are associated with the formation of amyloid plaques in Alzheimer's disease. By targeting these plaques, these antibodies aim to facilitate their clearance from the brain, potentially slowing the progression of neurodegeneration and improving cognitive function in patients.Examples include donanemab and lecanemab, which have been developed to treat early stages of Alzheimer's.

According to our (Global Info Research) latest study, the global Anti-amyloid-β Monoclonal Antibodies market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.

The market for anti-amyloid-β monoclonal antibodies is experiencing rapid growth, driven by the increasing prevalence of Alzheimer's disease and the recent approval of innovative therapies like donanemab and lecanemab. This surge is fueled by heightened awareness and demand for disease-modifying treatments that address the underlying pathology of Alzheimer's rather than just symptomatic relief.Challenges such as pricing, accessibility, and long-term efficacy remain, but the overall trend indicates a significant shift towards targeting amyloid pathology in Alzheimer's therapy, promising a transformative impact on patient care and market growth.

This report is a detailed and comprehensive analysis for global Anti-amyloid-β Monoclonal Antibodies market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:
Global Anti-amyloid-β Monoclonal Antibodies market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Anti-amyloid-β Monoclonal Antibodies market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Anti-amyloid-β Monoclonal Antibodies market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Anti-amyloid-β Monoclonal Antibodies market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Anti-amyloid-β Monoclonal Antibodies
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Anti-amyloid-β Monoclonal Antibodies market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eisai, Biogen, Eli Lilly, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation
Anti-amyloid-β Monoclonal Antibodies market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Lecanemab
    Donanemab

Market segment by Application
    Hospital
    Clinic
    Other

Major players covered
    Eisai
    Biogen
    Eli Lilly

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Anti-amyloid-β Monoclonal Antibodies product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Anti-amyloid-β Monoclonal Antibodies, with price, sales quantity, revenue, and global market share of Anti-amyloid-β Monoclonal Antibodies from 2019 to 2024.
Chapter 3, the Anti-amyloid-β Monoclonal Antibodies competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anti-amyloid-β Monoclonal Antibodies breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Anti-amyloid-β Monoclonal Antibodies market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-amyloid-β Monoclonal Antibodies.
Chapter 14 and 15, to describe Anti-amyloid-β Monoclonal Antibodies sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Lecanemab
        1.3.3 Donanemab
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital
        1.4.3 Clinic
        1.4.4 Other
    1.5 Global Anti-amyloid-β Monoclonal Antibodies Market Size & Forecast
        1.5.1 Global Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity (2019-2030)
        1.5.3 Global Anti-amyloid-β Monoclonal Antibodies Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 Eisai
        2.1.1 Eisai Details
        2.1.2 Eisai Major Business
        2.1.3 Eisai Anti-amyloid-β Monoclonal Antibodies Product and Services
        2.1.4 Eisai Anti-amyloid-β Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Eisai Recent Developments/Updates
    2.2 Biogen
        2.2.1 Biogen Details
        2.2.2 Biogen Major Business
        2.2.3 Biogen Anti-amyloid-β Monoclonal Antibodies Product and Services
        2.2.4 Biogen Anti-amyloid-β Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Biogen Recent Developments/Updates
    2.3 Eli Lilly
        2.3.1 Eli Lilly Details
        2.3.2 Eli Lilly Major Business
        2.3.3 Eli Lilly Anti-amyloid-β Monoclonal Antibodies Product and Services
        2.3.4 Eli Lilly Anti-amyloid-β Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Eli Lilly Recent Developments/Updates

3 Competitive Environment: Anti-amyloid-β Monoclonal Antibodies by Manufacturer
    3.1 Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Manufacturer (2019-2024)
    3.3 Global Anti-amyloid-β Monoclonal Antibodies Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Anti-amyloid-β Monoclonal Antibodies by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Anti-amyloid-β Monoclonal Antibodies Manufacturer Market Share in 2023
        3.4.3 Top 6 Anti-amyloid-β Monoclonal Antibodies Manufacturer Market Share in 2023
    3.5 Anti-amyloid-β Monoclonal Antibodies Market: Overall Company Footprint Analysis
        3.5.1 Anti-amyloid-β Monoclonal Antibodies Market: Region Footprint
        3.5.2 Anti-amyloid-β Monoclonal Antibodies Market: Company Product Type Footprint
        3.5.3 Anti-amyloid-β Monoclonal Antibodies Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Anti-amyloid-β Monoclonal Antibodies Market Size by Region
        4.1.1 Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Region (2019-2030)
        4.1.2 Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Region (2019-2030)
        4.1.3 Global Anti-amyloid-β Monoclonal Antibodies Average Price by Region (2019-2030)
    4.2 North America Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030)
    4.3 Europe Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030)
    4.4 Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030)
    4.5 South America Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030)
    4.6 Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2019-2030)
    5.2 Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Type (2019-2030)
    5.3 Global Anti-amyloid-β Monoclonal Antibodies Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2019-2030)
    6.2 Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Application (2019-2030)
    6.3 Global Anti-amyloid-β Monoclonal Antibodies Average Price by Application (2019-2030)

7 North America
    7.1 North America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2019-2030)
    7.2 North America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2019-2030)
    7.3 North America Anti-amyloid-β Monoclonal Antibodies Market Size by Country
        7.3.1 North America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Country (2019-2030)
        7.3.2 North America Anti-amyloid-β Monoclonal Antibodies Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2019-2030)
    8.2 Europe Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2019-2030)
    8.3 Europe Anti-amyloid-β Monoclonal Antibodies Market Size by Country
        8.3.1 Europe Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Country (2019-2030)
        8.3.2 Europe Anti-amyloid-β Monoclonal Antibodies Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Market Size by Region
        9.3.1 Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 South Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2019-2030)
    10.2 South America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2019-2030)
    10.3 South America Anti-amyloid-β Monoclonal Antibodies Market Size by Country
        10.3.1 South America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Country (2019-2030)
        10.3.2 South America Anti-amyloid-β Monoclonal Antibodies Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Market Size by Country
        11.3.1 Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Anti-amyloid-β Monoclonal Antibodies Market Drivers
    12.2 Anti-amyloid-β Monoclonal Antibodies Market Restraints
    12.3 Anti-amyloid-β Monoclonal Antibodies Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Anti-amyloid-β Monoclonal Antibodies and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Anti-amyloid-β Monoclonal Antibodies
    13.3 Anti-amyloid-β Monoclonal Antibodies Production Process
    13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Anti-amyloid-β Monoclonal Antibodies Typical Distributors
    14.3 Anti-amyloid-β Monoclonal Antibodies Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Table 2. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Table 3. Eisai Basic Information, Manufacturing Base and Competitors
 Table 4. Eisai Major Business
 Table 5. Eisai Anti-amyloid-β Monoclonal Antibodies Product and Services
 Table 6. Eisai Anti-amyloid-β Monoclonal Antibodies Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 7. Eisai Recent Developments/Updates
 Table 8. Biogen Basic Information, Manufacturing Base and Competitors
 Table 9. Biogen Major Business
 Table 10. Biogen Anti-amyloid-β Monoclonal Antibodies Product and Services
 Table 11. Biogen Anti-amyloid-β Monoclonal Antibodies Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 12. Biogen Recent Developments/Updates
 Table 13. Eli Lilly Basic Information, Manufacturing Base and Competitors
 Table 14. Eli Lilly Major Business
 Table 15. Eli Lilly Anti-amyloid-β Monoclonal Antibodies Product and Services
 Table 16. Eli Lilly Anti-amyloid-β Monoclonal Antibodies Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 17. Eli Lilly Recent Developments/Updates
 Table 18. Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Manufacturer (2019-2024) & (K Units)
 Table 19. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Manufacturer (2019-2024) & (USD Million)
 Table 20. Global Anti-amyloid-β Monoclonal Antibodies Average Price by Manufacturer (2019-2024) & (US$/Unit)
 Table 21. Market Position of Manufacturers in Anti-amyloid-β Monoclonal Antibodies, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
 Table 22. Head Office and Anti-amyloid-β Monoclonal Antibodies Production Site of Key Manufacturer
 Table 23. Anti-amyloid-β Monoclonal Antibodies Market: Company Product Type Footprint
 Table 24. Anti-amyloid-β Monoclonal Antibodies Market: Company Product Application Footprint
 Table 25. Anti-amyloid-β Monoclonal Antibodies New Market Entrants and Barriers to Market Entry
 Table 26. Anti-amyloid-β Monoclonal Antibodies Mergers, Acquisition, Agreements, and Collaborations
 Table 27. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
 Table 28. Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Region (2019-2024) & (K Units)
 Table 29. Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Region (2025-2030) & (K Units)
 Table 30. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Region (2019-2024) & (USD Million)
 Table 31. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Region (2025-2030) & (USD Million)
 Table 32. Global Anti-amyloid-β Monoclonal Antibodies Average Price by Region (2019-2024) & (US$/Unit)
 Table 33. Global Anti-amyloid-β Monoclonal Antibodies Average Price by Region (2025-2030) & (US$/Unit)
 Table 34. Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2019-2024) & (K Units)
 Table 35. Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2025-2030) & (K Units)
 Table 36. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Type (2019-2024) & (USD Million)
 Table 37. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Type (2025-2030) & (USD Million)
 Table 38. Global Anti-amyloid-β Monoclonal Antibodies Average Price by Type (2019-2024) & (US$/Unit)
 Table 39. Global Anti-amyloid-β Monoclonal Antibodies Average Price by Type (2025-2030) & (US$/Unit)
 Table 40. Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
 Table 41. Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
 Table 42. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Application (2019-2024) & (USD Million)
 Table 43. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Application (2025-2030) & (USD Million)
 Table 44. Global Anti-amyloid-β Monoclonal Antibodies Average Price by Application (2019-2024) & (US$/Unit)
 Table 45. Global Anti-amyloid-β Monoclonal Antibodies Average Price by Application (2025-2030) & (US$/Unit)
 Table 46. North America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2019-2024) & (K Units)
 Table 47. North America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2025-2030) & (K Units)
 Table 48. North America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
 Table 49. North America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
 Table 50. North America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
 Table 51. North America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
 Table 52. North America Anti-amyloid-β Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
 Table 53. North America Anti-amyloid-β Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
 Table 54. Europe Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2019-2024) & (K Units)
 Table 55. Europe Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2025-2030) & (K Units)
 Table 56. Europe Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
 Table 57. Europe Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
 Table 58. Europe Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
 Table 59. Europe Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
 Table 60. Europe Anti-amyloid-β Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
 Table 61. Europe Anti-amyloid-β Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
 Table 62. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2019-2024) & (K Units)
 Table 63. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2025-2030) & (K Units)
 Table 64. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
 Table 65. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
 Table 66. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Region (2019-2024) & (K Units)
 Table 67. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Region (2025-2030) & (K Units)
 Table 68. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Consumption Value by Region (2019-2024) & (USD Million)
 Table 69. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Consumption Value by Region (2025-2030) & (USD Million)
 Table 70. South America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2019-2024) & (K Units)
 Table 71. South America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2025-2030) & (K Units)
 Table 72. South America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
 Table 73. South America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
 Table 74. South America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
 Table 75. South America Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
 Table 76. South America Anti-amyloid-β Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
 Table 77. South America Anti-amyloid-β Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
 Table 78. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2019-2024) & (K Units)
 Table 79. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Type (2025-2030) & (K Units)
 Table 80. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
 Table 81. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
 Table 82. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
 Table 83. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
 Table 84. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
 Table 85. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
 Table 86. Anti-amyloid-β Monoclonal Antibodies Raw Material
 Table 87. Key Manufacturers of Anti-amyloid-β Monoclonal Antibodies Raw Materials
 Table 88. Anti-amyloid-β Monoclonal Antibodies Typical Distributors
 Table 89. Anti-amyloid-β Monoclonal Antibodies Typical Customers


List of Figures
 Figure 1. Anti-amyloid-β Monoclonal Antibodies Picture
 Figure 2. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Type, (USD Million), 2019 & 2023 & 2030
 Figure 3. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Type in 2023
 Figure 4. Lecanemab Examples
 Figure 5. Donanemab Examples
 Figure 6. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Figure 7. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Application in 2023
 Figure 8. Hospital Examples
 Figure 9. Clinic Examples
 Figure 10. Other Examples
 Figure 11. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value, (USD Million): 2019 & 2023 & 2030
 Figure 12. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value and Forecast (2019-2030) & (USD Million)
 Figure 13. Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity (2019-2030) & (K Units)
 Figure 14. Global Anti-amyloid-β Monoclonal Antibodies Price (2019-2030) & (US$/Unit)
 Figure 15. Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Manufacturer in 2023
 Figure 16. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Manufacturer in 2023
 Figure 17. Producer Shipments of Anti-amyloid-β Monoclonal Antibodies by Manufacturer Sales ($MM) and Market Share (%): 2023
 Figure 18. Top 3 Anti-amyloid-β Monoclonal Antibodies Manufacturer (Revenue) Market Share in 2023
 Figure 19. Top 6 Anti-amyloid-β Monoclonal Antibodies Manufacturer (Revenue) Market Share in 2023
 Figure 20. Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Region (2019-2030)
 Figure 21. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value Market Share by Region (2019-2030)
 Figure 22. North America Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 23. Europe Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 24. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 25. South America Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 26. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 27. Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Type (2019-2030)
 Figure 28. Global Anti-amyloid-β Monoclonal Antibodies Consumption Value Market Share by Type (2019-2030)
 Figure 29. Global Anti-amyloid-β Monoclonal Antibodies Average Price by Type (2019-2030) & (US$/Unit)
 Figure 30. Global Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
 Figure 31. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Application (2019-2030)
 Figure 32. Global Anti-amyloid-β Monoclonal Antibodies Average Price by Application (2019-2030) & (US$/Unit)
 Figure 33. North America Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Type (2019-2030)
 Figure 34. North America Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
 Figure 35. North America Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
 Figure 36. North America Anti-amyloid-β Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
 Figure 37. United States Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 38. Canada Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 39. Mexico Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 40. Europe Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Type (2019-2030)
 Figure 41. Europe Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
 Figure 42. Europe Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
 Figure 43. Europe Anti-amyloid-β Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
 Figure 44. Germany Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 45. France Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 46. United Kingdom Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 47. Russia Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 48. Italy Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 49. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Type (2019-2030)
 Figure 50. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
 Figure 51. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Region (2019-2030)
 Figure 52. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Consumption Value Market Share by Region (2019-2030)
 Figure 53. China Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 54. Japan Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 55. South Korea Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 56. India Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 57. Southeast Asia Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 58. Australia Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 59. South America Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Type (2019-2030)
 Figure 60. South America Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
 Figure 61. South America Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
 Figure 62. South America Anti-amyloid-β Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
 Figure 63. Brazil Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 64. Argentina Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 65. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Type (2019-2030)
 Figure 66. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
 Figure 67. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
 Figure 68. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
 Figure 69. Turkey Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 70. Egypt Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 71. Saudi Arabia Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 72. South Africa Anti-amyloid-β Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
 Figure 73. Anti-amyloid-β Monoclonal Antibodies Market Drivers
 Figure 74. Anti-amyloid-β Monoclonal Antibodies Market Restraints
 Figure 75. Anti-amyloid-β Monoclonal Antibodies Market Trends
 Figure 76. Porters Five Forces Analysis
 Figure 77. Manufacturing Cost Structure Analysis of Anti-amyloid-β Monoclonal Antibodies in 2023
 Figure 78. Manufacturing Process Analysis of Anti-amyloid-β Monoclonal Antibodies
 Figure 79. Anti-amyloid-β Monoclonal Antibodies Industrial Chain
 Figure 80. Sales Channel: Direct to End-User vs Distributors
 Figure 81. Direct Channel Pros & Cons
 Figure 82. Indirect Channel Pros & Cons
 Figure 83. Methodology
 Figure 84. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Eisai
Biogen
Eli Lilly

Related Reports

Global Anti-amyloid-β Monoclonal Antibodies Supply, Demand and Key Producers, 2024-2030

Global Anti-amyloid-β Monoclonal Antibodies Supply, Demand and Key Producers, 2024-2030

date 27 Oct 2024

date Pharma & Healthcare

Anti-amyloid-β monoclonal antibodies are a class of targeted biologic therapies designed to bind specifically to amyloid-beta peptides in the brain, which are associated with the formation of amyloid plaques in Alzheimer's disease. By targeting these plaques, these antibodies aim to facilitate their clearance from the brain, potentially slowing the progression of neurodegeneration and improving cognitive function in patients.Examples include donanemab and lecanemab, which have been developed to treat early stages of Alzheimer's.

Product Tags

Anti-amyloid-β Monoclonal Antibodies

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>